Autonomix Medical to Unveil Long-Term Pain Relief Data for Pancreatic Cancer at ECIO 2026
Event summary
- Autonomix Medical will present long-term clinical data on pain mitigation in pancreatic cancer at ECIO 2026 on April 29, 2026.
- The presentation, titled 'Pain mitigation in pancreatic adenocarcinoma: a long-term analysis of denervation via transvascular RF energy-based ablation,' will be delivered by Nikola Cesarovic, PhD.
- Autonomix's technology aims to provide durable pain relief through transvascular radiofrequency ablation.
- The company's platform technology includes a catheter-based microchip sensing array for neural signal detection.
The big picture
Autonomix Medical's presentation at ECIO 2026 highlights the growing focus on precision nerve-targeted treatments in oncology. The company's transvascular RF ablation approach addresses a significant unmet need in pancreatic cancer pain management, a condition with limited effective solutions. Success in this area could position Autonomix as a key player in the interventional oncology space, with potential applications extending to other chronic pain and neurological conditions.
What we're watching
- Clinical Efficacy
- How the long-term data will impact the perception of Autonomix's technology as a viable solution for pancreatic cancer pain management.
- Market Expansion
- Whether Autonomix can leverage this data to expand into other indications beyond pancreatic cancer.
- Regulatory Pathway
- The pace at which Autonomix can progress towards regulatory approval for its investigational technology.
Our editorial coverage:
Related topics